178 46

Full metadata record

DC FieldValueLanguage
dc.contributor.author윤아일린-
dc.date.accessioned2022-04-12T00:18:46Z-
dc.date.available2022-04-12T00:18:46Z-
dc.date.issued2020-08-
dc.identifier.citationCLINICAL AND MOLECULAR HEPATOLOGY, v. 26, no. 4, page. 411-429en_US
dc.identifier.issn2287-2728-
dc.identifier.issn2287-285X-
dc.identifier.urihttps://www.e-cmh.org/journal/view.php?doi=10.3350/cmh.2020.0049-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/169900-
dc.description.abstractClinical practice guidelines are important for guiding the management of specific diseases by medical practitioners, trainees, and nurses. In some cases, the guidelines are utilized as a reference for health policymakers in controlling diseases with a large public impact. With this in mind, practice guidelines for the management of chronic hepatitis B (CHB) have been developed in the United States, Europe, and Asian-Pacific regions to suggest the best-fit recommendations for each social and medical circumstance. Recently, the Korean Association for the Study of the Liver published a revised version of its clinical practice guidelines for the management of CHB. The guidelines included updated information based on newly available antiviral agents, the most recent opinion on the initiation and cessation of treatment, and updates for the management of drug resistance, partial virological response, and side effects. Additionally, CHB management in specific situations was comprehensively revised. This review compares the similarities and differences among the various practice guidelines to identify unmet needs and improve future recommendations.en_US
dc.description.sponsorshipThis work was funded in part by the Korean Association for the Study of the Liver and Korea University Research Grants.en_US
dc.language.isoenen_US
dc.publisherKOREAN ASSOC STUDY LIVERen_US
dc.subjectHepatitis Ben_US
dc.subjectChronicen_US
dc.subjectHepatitis B virusen_US
dc.subjectClinical practice guidelinesen_US
dc.titleComparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stopen_US
dc.typeArticleen_US
dc.identifier.doi10.3350/cmh.2020.0049-
dc.relation.journalCLINICAL AND MOLECULAR HEPATOLOGY-
dc.contributor.googleauthorYim, Hyung Joon-
dc.contributor.googleauthorKim, Ji Hoon-
dc.contributor.googleauthorPark, Jun Yong-
dc.contributor.googleauthorYoon, Eileen L.-
dc.contributor.googleauthorPark, Hana-
dc.contributor.googleauthorKwon, Jung Hyun-
dc.contributor.googleauthorSinn, Dong Hyun-
dc.contributor.googleauthorLee, Sae Hwan-
dc.contributor.googleauthorLee, Jeong-Hoon-
dc.contributor.googleauthorLee, Hyun Woong-
dc.relation.code2020048401-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidmseileen80-
dc.identifier.orcidhttps://orcid.org/0000-0003-0474-048X-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE